Qualcomm posts bonds to ban Apple iPhone sales in Germany
The payment of €1.34 billion in security bonds allows Qualcomm to enforce a court order that will ban sales of some Apple iPhones in Germany over a patent issue
Bengaluru/Munich: Qualcomm Inc. said on Thursday it posted security bonds of €1.34 billion ($1.52 billion) in order to be able to enforce a court order that will ban sales of some Apple iPhones in Germany. The chipmaker needed to post the bonds as part of a legal requirement by a German court, which on 20 December found that Apple had infringed Qualcomm patents on power saving technology used in iPhones.
The iPhone maker had earlier said it would pull some older models from its German stores.
According to the court order, Apple has to stop the sale, offer for sale and importation for sale of all infringing iPhones in Germany. Apple had said it was appealing the decision, but the order goes into effect as soon as Qualcomm posts the bond.
The court also ordered Apple to recall infringing iPhones from third party resellers in Germany, according to a statement by Qualcomm.
Munich regional court and Apple were not immediately available for comment.
The German case is Qualcomm’s third major effort to secure a ban on Apple’s lucrative iPhones over patent infringement allegations after similar moves in the US and China, and part of the ongoing global patent skirmish between the two companies.
Editor's Picks »
- Etihad will invest in debt-laden Jet Airways, but conditions apply: Reports
- Redmi Note 7’s flash sale will give us an idea of smartphone sales this year
- Indra Nooyi being considered to head World Bank
- SC agrees to hear challenge to Nageswara Rao’s appointment as interim CBI director
- Facebook advertising rules to become stricter for Lok Sabha election
- Why Tata Motors’ Project Charge at JLR is failing to recharge its shares
- Outlook on global profit growth worst since 2008 financial crisis
- Q3 results: ICICI Securities loses its retail broking crown
- High drug approvals to keep up pricing pressure for pharma firms
- Roads sector: Toll collections set to surge, but risks loom for developers